Low Molecular Weight Heparin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Low Molecular Heparin Market is Segmented by Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fondaparinux and Others), Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Other Applications) End-Users (Hospitals and Clinics, Ambulatory Surgical Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Low Molecular Weight Heparin Market Size

Single User License
Team License
Corporate License
Book before:
Low Molecular Weight Heparin Market Size
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.60 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Global Low Molecular Weight Heparin Market

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Low Molecular Weight Heparin Market Analysis

The low molecular heparin market is expected to register a CAGR of 6.6% over the forecast period, 2022-2027.

The impact of COVID-19 on the low molecular heparin (LMWH) market was substantial in the initial phase owing to factors such as the closure of manufacturing facilities and research and development activities. However, the increasing use of LMWH in treating COVID-19 patients has accelerated the demand for LMWH products within the market. For instance, according to the PubMed Central (PMC) article titled "COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis," published in May 2020, LMWH has antiviral characteristics in-vitro, and it is used in COVID-19 patients to prevent or delay coagulation cascade activation caused by inflammation. Disseminated intravascular coagulation and venous thromboembolism are two serious and potentially fatal complications. Moreover, there are currently many ongoing randomized controlled trials investigating the use of different heparin doses in patients with COVID-19. For instance, the clinical trial titled "a randomized controlled trial initiated in June 2020, comparing efficacy and safety of high versus low low-molecular-weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol" was to determine whether high doses of LMWH are effective in preventing thromboembolism, myocardial infarction, need for ventilation, and death. Thus, the abovementioned factors are likely to positively impact the adoption of LMWH among patients, ultimately driving the market growth over the pandemic phase.

The increasing prevalence of blood disorders and the introduction of LMWH anticoagulants are among the major factors driving the growth of the studied market. For instance, according to the Office of Disease Prevention & Health Promotion (ODPHP) data published in 2020, blood clots in leg veins affect roughly 1.2 million Americans yearly. This condition is called deep venous thrombosis (DVT). DVT is the most common preventable cause of death in hospitals, accounting for 10% of all deaths from pulmonary embolism (PE), which occurs when a blood clot from a vein in the leg travels to the lungs. Similarly, according to the Leukemia and Lymphoma Society (LLS) Factsheet 2021, one person in the United States is diagnosed with blood cancer approximately every three minutes.

Moreover, as per the same source, 186,400 people in the United States will be diagnosed with leukemia and lymphoma in 2021. In addition, 825,651 people lived with lymphoma in the United States; 152,671 people lived with Hodgkin's lymphoma, and 672,980 people lived with non-Hodgkin's lymphoma. As LMWH is extensively used in preventing blood clots and treating venous thromboembolism (deep vein thrombosis and pulmonary embolism), blood cancers, and the treatment of myocardial infarction, such an increase in the patient population will eventually drive the demand for low-molecular-weight heparin products.

Additionally, according to the National Institutes of Health (NIH) data published in February 2022, LMWH such as dalteparin and enoxaparin is used to prevent venous thromboembolic disease (VTE) during an acute or elective hospital stay, as well as to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). As per the same source, over half of the patients admitted to hospitals who are severely ill are at risk of thromboembolic illness, and VTE is responsible for 5% to 10% of hospital mortality, necessitating accurate VTE risk assessment and effective treatment. Such instances will likely positively impact the market's growth over the forecast period.

In addition, new product approvals and strategic activities by major market players are augmenting the market's growth. For instance, in May 2021, Dr. Reddy's Laboratories Ltd. launched Ertapenem for Injection, one g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection). Likewise, in May 2020, Meitheal Pharmaceuticals Inc. received FDA approval for Enoxaparin Sodium Injection (USP), a generic equivalent of Lovenox, to prevent and treat harmful blood clots. Thus, due to product launches and acquisitions, the studied market is expected to grow significantly over the forecast period. Therefore, owing to the factors mentioned earlier, the studied market is anticipated to witness growth over the analysis period. However, the adverse effects of low molecular weight heparin are likely to impede the market growth.

Low Molecular Weight Heparin Market Trends

This section covers the major market trends shaping the Low Molecular Weight Heparin Market according to our research experts:

Deep Vein Thrombosis Segment is Expected to Witness Significant Growth Over the Forecast Period

Deep vein thrombosis (DVT), also known as venous thrombosis, occurs when a thrombus (blood clot) forms in veins deep within the body due to injury to the veins or sluggish blood flow. Blood clots can fully or partially stop blood flow through a vein. DVTs are commonly found in the lower leg, thigh, or pelvis but can also occur in the arm, brain, intestines, liver, or kidney.

The increasing prevalence of DVT is one of the major factors driving the segment's growth. For instance, according to the National Institutes of Health (NIH) article "Deep Vein Thrombosis," published in August 2021, the annual incidence of DVT is estimated to be 80 cases per 100,000, with a lower limb DVT frequency of 1 case per 1000 people. More than 200,000 people in the United States experience venous thrombosis each year, with 50,000 occurrences including pulmonary embolism. As LMWHs are more effective than no prophylaxis in preventing DVT and pulmonary thromboembolism in high-risk general surgical patients, the demand for LMWH in patients suffering from DVT is anticipated to increase over the coming years, in turn driving the segment growth. Hence, owing to the above factors, the adoption of these products will likely increase among the target population, driving the segment growth.

Global

North America is Expected to Dominate the Low Molecular Weight Heparin Market

North America is expected to dominate the market owing to factors such as the growing disease burden, the rising geriatric population, and the rising number of product approvals. According to the Department of Economic and Social Affairs of the United Nations, the elderly population is expected to rise from 26.6 million in 2003 to 36.0 million by 2020 in the United States, a 35% increase. As the risk of venous thromboembolism is strongly associated with age, the demand for LMWH will likely bolster soon.

Likewise, as per the article titled "Data and Statistics on Venous Thromboembolism," published by the Centers for Disease Control and Prevention in 2020, the precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown. However, it is estimated that up to 900,000 people in the United States are affected yearly. Furthermore, deep venous thrombosis (DVT), which leads to pulmonary embolism (PE), is the third most common cardiovascular disease after myocardial infarction and stroke. Such an increase in the target population will ultimately boost the adoption of LMWH products, thereby positively impacting the market growth.

Key initiatives and a high concentration of market players or manufacturers' presence in the United States are some of the other factors driving the growth of the low molecular heparin market in the country. For instance, in July 2020, Novartis announced a new initiative to help patients access affordable medicines to treat the major symptoms of COVID-19, a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and lead to death in some people, putting an immense strain on fragile healthcare systems. Therefore, owing to the factors mentioned earlier, the growth of the studied market is anticipated to boost in the North American region.

Low Molecular Weight Heparin Market Forecast

Low Molecular Weight Heparin Industry Overview

The low molecular heparin market is moderately competitive due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies holding major market shares. Some key players include Aspen Holdings, Changzhou Qianhong Bio-Pharma, Leopharma A/S, Teva Pharmaceutical Industries Ltd., B. Braun Medical, Inc., Pfizer, Inc., Sanofi, Dr. Reddy's Laboratories Limited, Abbott, and Novartis AG, among others.

Low Molecular Weight Heparin Market Leaders

  1. Aspen Holdings

  2. Changzhou Qianhong Bio-Pharma

  3. B. Braun Medical, Inc.

  4. Pfizer, Inc.

  5. Dr. Reddy's Laboratories Limited

*Disclaimer: Major Players sorted in no particular order

Aspen Holdings, Changzhou Qianhong Bio-Pharma, Leopharma A/S, Teva Pharmaceutical Industries Ltd., B. Braun Medical, Inc., Pfizer, Inc., Sanofi, Dr. Reddy's Laboratories Limited, Abbott, and Novartis AG
bookmark Need More Details on Market Players and Competitors?
Download PDF

Low Molecular Weight Heparin Market News

  • In August 2022, Momenta Pharmaceuticals, Inc. announced the product approval of M-Enoxaparin with the United States Food and Drug Administration (FDA). Momenta is developing M-Enoxaparin, a technology-enabled generic version of Lovenox, in collaboration with Sandoz, the generics division of Novartis AG.
  • In April 2021, Valeo Pharma Inc., a Canadian pharmaceutical company, announced that commercial shipments of Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, have commenced across Canada.

Low Molecular Weight Heparin Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Prevalence of Blood Disorders Worldwide

      2. 4.2.2 Introduction of LMWH Anticoagulants

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects of Low Molecular Weight Heparin

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product Type

      1. 5.1.1 Enoxaparin

      2. 5.1.2 Dalteparin

      3. 5.1.3 Tinzaparin

      4. 5.1.4 Fondaparinux

      5. 5.1.5 Others

    2. 5.2 By Application

      1. 5.2.1 Deep Vein Thrombosis

      2. 5.2.2 Acute coronary syndrome (ACS)

      3. 5.2.3 Pulmonary Embolism

      4. 5.2.4 Others (Aerial Thrombosis, Bypass Surgery, Kidney Dialysis, and Blood Transfusions )

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Ambulatory Surgical Centers

      4. 5.3.4 Others (Pharmaceutical and Biotechnology Companies and Research Laboratories and Institutes)

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Aspen Holdings

      2. 6.1.2 Changzhou Qianhong Bio-Pharma

      3. 6.1.3 Leopharma A/S

      4. 6.1.4 Teva Pharmaceutical Industries Ltd.

      5. 6.1.5 B. Braun Medical, Inc.

      6. 6.1.6 Pfizer, Inc.

      7. 6.1.7 Sanofi

      8. 6.1.8 Dr. Reddy's Laboratories Limited

      9. 6.1.9 Abbott Laboratories

      10. 6.1.10 Novartis AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Low Molecular Weight Heparin Industry Segmentation

As per the report's scope, low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to prevent blood clots and to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and myocardial infarction. According to the Nonclinical Development of Novel Biologics, Biosimilars, Vaccines, and Specialty Biologics, LMWHs are defined as heparin salts with an average molecular weight of less than 8,000 Da and in which at least 60% of all chains have a molecular weight of less than 8,000 Da. These are obtained by various methods of fractionation or depolymerization of polymeric heparin. The low molecular heparin market is segmented by product type (enoxaparin, dalteparin, tinzaparin, fondaparinux, and others), application (deep vein thrombosis, acute coronary syndrome (acs), pulmonary embolism, and other applications) end-users (hospitals and clinics, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.

By Product Type
Enoxaparin
Dalteparin
Tinzaparin
Fondaparinux
Others
By Application
Deep Vein Thrombosis
Acute coronary syndrome (ACS)
Pulmonary Embolism
Others (Aerial Thrombosis, Bypass Surgery, Kidney Dialysis, and Blood Transfusions )
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
Others (Pharmaceutical and Biotechnology Companies and Research Laboratories and Institutes)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Low Molecular Weight Heparin Market Research FAQs

The Global Low Molecular Weight Heparin Market is projected to register a CAGR of 6.60% during the forecast period (2024-2029)

Aspen Holdings, Changzhou Qianhong Bio-Pharma, B. Braun Medical, Inc., Pfizer, Inc. and Dr. Reddy's Laboratories Limited are the major companies operating in the Global Low Molecular Weight Heparin Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global Low Molecular Weight Heparin Market.

The report covers the Global Low Molecular Weight Heparin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Low Molecular Weight Heparin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Global Low Molecular Weight Heparin Industry Report

Statistics for the 2024 Global Low Molecular Weight Heparin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Low Molecular Weight Heparin analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Low Molecular Weight Heparin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)